Predictors of the use of complementary and alternative medicine (CAM) by women at high risk for breast cancer

European Journal of Cancer

Volumn 45, Issue 4, 2009, Pages 551-560

  Field, K M ^a   Jenkins, M A ^b   Friedlander, M L ^c   McKinley, J M ^a   Price, M A ^d   Weideman, P ^a   Keogh, L A ^b   McLachlan, S A ^b,e   Lindeman, G J ^f   Hopper, J L ^b   Butow, P N ^d   Phillips, K A ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Alternative medicine; BRCA1; BRCA2; Breast cancer; CAM; Chemoprevention; Complementary medicine; Familial; Ovarian cancer; Tamoxifen

Indexed keywords

MINERAL; VITAMIN;

ADULT; AGED; ALTERNATIVE MEDICINE; ANXIETY; ARTICLE; BREAST CANCER; CANCER PREVENTION; CONTROLLED STUDY; EDUCATIONAL STATUS; FAMILY HISTORY; FEMALE; HIGH RISK POPULATION; HUMAN; LOW FAT DIET; MEDITATION; OSTEOPATHIC MEDICINE; PHYSICAL ACTIVITY; PHYSIOTHERAPY; PRIORITY JOURNAL; QUESTIONNAIRE; SELF REPORT; SMOKING; VEGETARIAN DIET;

ADULT; AGED; AGED, 80 AND OVER; ANXIETY; ATTITUDE TO HEALTH; AUSTRALIA; BRCA2 PROTEIN; BREAST NEOPLASMS; COMPLEMENTARY THERAPIES; EDUCATIONAL STATUS; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; MOTOR ACTIVITY; MUTATION; NEOPLASTIC SYNDROMES, HEREDITARY; NEW ZEALAND; UBIQUITIN-PROTEIN LIGASES; YOUNG ADULT;

EID: 60349089549     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.09.023     Document Type: Article

References (32)

1. Scott C.L., Jenkins M.A., Southey M.C., et al. Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics. Hum Genet 112 5-6 (2003) 542-551
2. Field K., and Phillips K. Management of women at high familial risk for breast and ovarian cancer. Cancer Forum 31 3 (2007) 141-149
3. Statement on complementary and alternative therapies. National Centre for Complementary and Alternative Medicine, 2004. .
4. Xue C.C., Zhang A.L., Lin V., Da Costa C., and Story D.F. Complementary and alternative medicine use in Australia: a national population-based survey. J Altern Complement Med 13 6 (2007) 643-650
5. MacLennan A.H., Myers S.P., and Taylor A.W. The continuing use of complementary and alternative medicine in South Australia: costs and beliefs in 2004. Med J Aust 184 1 (2006) 27-31
6. Richardson M.A., Sanders T., Palmer J.L., Greisinger A., and Singletary S.E. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18 13 (2000) 2505-2514
7. Malekzadeh F., Rose C., Ingvar C., and Jernstrom H. Natural remedies and hormone preparations - potential risk for breast cancer patients A study surveys the use of agents which possibly counteract with the treatment. Lakartidningen 102 44 (2005) 3226-3228, 3230-1
8. Sparreboom A., Cox M.C., Acharya M.R., and Figg W.D. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 22 12 (2004) 2489-2503
9. Bjelakovic G., Nikolova D., Gluud L.L., Simonetti R.G., and Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. Jama 297 8 (2007) 842-857
10. Mann G.J., Thorne H., Balleine R.L., et al. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res 8 1 (2006) R12
11. Phillips K.A., Butow P.N., Stewart A.E., et al. Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort. Fam Cancer 4 2 (2005) 105-113
12. Horowitz M., Wilner N., and Alvarez W. Impact of Event Scale: a measure of subjective stress. Psychosom Med 41 3 (1979) 209-218
13. Zigmond A.S., and Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand 67 6 (1983) 361-370
14. Scheier M.F., and Carver C.S. Optimism, coping, and health: assessment and implications of generalized outcome expectancies. Health Psychol 4 3 (1985) 219-247
15. Broadhead W.E., Gehlbach S.H., de Gruy F.V., and Kaplan B.H. The Duke-UNC Functional Social Support Questionnaire. Measurement of social support in family medicine patients. Med Care 26 7 (1988) 709-723
16. Boon H., Stewart M., Kennard M.A., et al. Use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol 18 13 (2000) 2515-2521
17. World Health Organization: BMI classification. .
18. DiGianni L.M., Kim H.T., Emmons K., Gelman R., Kalkbrenner K.J., and Garber J.E. Complementary medicine use among women enrolled in a genetic testing program. Cancer Epidemiol Biomarkers Prev 12 4 (2003) 321-326
19. Alamian A., Rouleau I., Simard J., and Dorval M. Use of dietary supplements among women at high risk of hereditary breast and ovarian cancer (HBOC) tested for cancer susceptibility. Nutr Cancer 54 2 (2006) 157-165
20. Mueller C.M., Mai P.L., Bucher J., Peters J.A., Loud J.T., and Greene M.H. Complementary and alternative medicine use among women at increased genetic risk of breast and ovarian cancer. BMC Complement Altern Med 8 (2008) 17
21. Digianni L.M., Rue M., Emmons K., and Garber J.E. Complementary medicine use before and 1 year following genetic testing for BRCA1/2 mutations. Cancer Epidemiol Biomarkers Prev 15 1 (2006) 70-75
22. MacDonald D.J., Sarna L., Uman G.C., Grant M., and Weitzel J.N. Cancer screening and risk-reducing behaviors of women seeking genetic cancer risk assessment for breast and ovarian cancers. Oncol Nurs Forum 33 2 (2006) E27-35
23. Myers C.D., Jacobsen P.B., Huang Y., Frost M.H., Patten C.A., Cerhan J.R., et al. Familial and perceived risk of breast cancer in relation to use of complementary medicine. Cancer Epidemiol Biomarkers Prev 17 6 (2008) 1527-1534
24. Matthews A.K., Sellergren S.A., Huo D., List M., and Fleming G. Complementary and alternative medicine use among breast cancer survivors. J Altern Complement Med 13 5 (2007) 555-562
25. Goldstein M.S., Brown E.R., Ballard-Barbash R., Morgenstern H., Bastani R., Lee J., et al. The use of complementary and alternative medicine among california adults with and without cancer. Evid Based Complement Altern Med 2 4 (2005) 557-565
26. Nahin R.L., Dahlhamer J.M., Taylor B.L., et al. Health behaviors and risk factors in those who use complementary and alternative medicine. BMC Public Health 7 (2007) 217
27. Barnes P.M., Powell-Griner E., McFann K., and Nahin R.L. Complementary and alternative medicine use among adults: United States, 2002. Adv Data 343 (2004) 1-19
28. Rakovitch E., Pignol J.P., Chartier C., et al. Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death. Breast Cancer Res Treat 90 2 (2005) 139-148
29. Montazeri A., Sajadian A., Ebrahimi M., and Akbari M.E. Depression and the use of complementary medicine among breast cancer patients. Support Care Cancer 13 5 (2005) 339-342
30. Mueller C.M.P., Bucher J., Peters J., Loud J., and Greene M. Complementary and alternative medicine use among women at increased genetic risk of breast and ovarian cancer. BMC Complement Altern Med 8 (2008) 17
31. Ebadi M. Pharmacodynamic basis of herbal medicine. 2nd ed. (2006), CRC Press, Florida, USA
32. Mannel M. Drug interactions with St John's wort: mechanisms and clinical implications. Drug Saf 27 11 (2004) 773-797